p21 Inhibits Thr161 Phosphorylation of Cdc2 to Enforce the G2 DNA Damage Checkpoint
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The cyclin-dependent kinase inhibitor p21 is required for a sustained G(2) arrest after activation of the DNA damage checkpoint. Here we have addressed the mechanism by which p21 can contribute to this arrest in G(2). We show that p21 blocks the activating phosphorylation of Cdc2 on Thr(161). p21 does not interfere with the dephosphorylation of two inhibitory phosphorylation sites on Cdc2, Thr(14) and Tyr(15), indicating that p21 targets a different event in Cdc2 activation as the well described DNA damage checkpoint pathway involving Chk1 and Cdc25C. Taken together our data show that a cell is equipped with at least two independent pathways to ensure efficient inhibition of Cdc2 activity in response to DNA damage, influencing both positive and negative regulatory phosphorylation events on Cdc2.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“even after its overexpression in U2OS osteosarcoma cancer cells, p21 only weakly associated with cyclin B1-Cdk1).58”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [58]
In the citing paper
“They elegantly confirmed and extended previous observations 58,69 and pinpointed this event as the first step in triggering the G2 exit program, resulting in permanent cell cycle withdrawal (Fig. 3).”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [58]
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Morgan, D. O. (1995) · Nature · doi:10.1038/374131a0 · Cited by 3,284
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Boyle, W. J., van der Geer, P., & Hunter, T. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)01013-r · Cited by 1,434
Cyclin A is required at two points in the human cell cycle.
Pagano, M., Pepperkok, R., Verde, F., Ansorge, W., & Draetta, G. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05135.x · Cited by 1,403
Peng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., & Piwnica-Worms, H. (1997) · Science · doi:10.1126/science.277.5331.1501 · Cited by 1,341
Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., & Elledge, S. J. (1997) · Science · doi:10.1126/science.277.5331.1497 · Cited by 1,320
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251
Inhibition of cyclin-dependent kinases by p21.
Harper, J. W., Elledge, S. J., Keyomarsi, K., Dynlacht, B., Tsai, L. H., Zhang, P., Dobrowolski, S., Bai, C., Connell-Crowley, L., & Swindell, E. (1995) · Molecular Biology of the Cell · doi:10.1091/mbc.6.4.387 · Cited by 1,023
Hotamisligil, G. S., Johnson, R. S., Distel, R. J., Ellis, R., Papaioannou, V. E., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.274.5291.1377 · Cited by 918
Research works printed but not linked: 1
- Li, 1994, Oncogene, 9, 2261
Cited by
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
Regulation of the G2/M transition by p53
Taylor, W. R., & Stark, G. R. (2001) · Oncogene · doi:10.1038/sj.onc.1204252 · Cited by 1,559
“These results show that the inhibition of CAK by p53 may contribute to G2 arrest.”
BackgroundInfluentialRoninson, I. B. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00847-3 · Cited by 443
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
Shah, M. A., & Schwartz, G. K. (2001) · PubMed · Cited by 518
Multiple roles of the cell cycle inhibitor p21CDKN1A in the DNA damage response
Cazzalini, O., Scovassi, A. I., Savio, M., Stivala, L. A., & Prosperi, E. (2010) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2010.01.009 · Cited by 433
“in sustaining the G2 arrest in response to DNA damage [44].”
BackgroundMaier, P., Hartmann, L., Wenz, F., & Herskind, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010102 · Cited by 414
“Enhanced expression of p21 in response to activated p53 also blocks transition from the G2 to M phase; p21 binds the CDK1-cyclinB complex, thereby preventing its activation [35].”
BackgroundChecking out the G2/M transition
Smits, V. A. J., & Medema, R. H. (2001) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(01)00204-4 · Cited by 355
Self-citationForced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Aarts, M., Sharpe, R., Garcia-Murillas, I., Gevensleben, H., Hurd, M. S., Shumway, S. D., Toniatti, C., Ashworth, A., & Turner, N. C. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0320 · Cited by 327
“p53 and p21 inhibit mitotic gene transcription in response to DNA damage switching the LINC complex from active to repressive states (22, 29) and p21 directly inhibits CDK1 activity (30-32).”
BackgroundThe p53 tumor suppressor participates in multiple cell cycle checkpoints
Giono, L. E., & Manfredi, J. J. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20689 · Cited by 328
“A number of p53 target genes ensure the maintenance of this arrest: p21 inhibits the cdc2/B complex, as well as its activating kinase CAK; GADD45 promotes dissociation of the cdc2/ B complex; 14-3-3 s sequesters cdc2/B in the cytoplasm; Cdc25C expression is repressed by p53.”
BackgroundInfluentialSenescence from G2 arrest, revisited
Gire, V., & Dulić, V. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1000134 · Cited by 300
“The uncertainty regarding the role of p21 in the G2/M checkpoint was further supported by the findings that in p53-deficient cells arrested in G2, cyclin B1-Cdk1 complexes are inactive(57) and that even after its overexpression in U2OS osteosarcoma cancer cells, p21 only weakly associated with cyclin B1-Cdk1).(58) Bas…”
BackgroundThe common and distinct target genes of the p53 family transcription factors
Harms, K., Nozell, S., & Chen, X. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3304-4 · Cited by 295
p53 modulation of the DNA damage response
Helton, E. S., & Chen, X. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21091 · Cited by 293
“…p21 which blocks G2/M progression by binding the Cdc2–cyclinB complex and preventing the activating phosphorylation of Cdc2 at Thr161 byCAK [Smits et al., 2000]. p53 also induces 14- 3-3swhich blocks entry into mitosis by promoting Wee1 kinase activity and by sequestering Cdc25C…”
BackgroundControl of the G2/M Transition
Stark, G. R., & Taylor, W. R. (2006) · Molecular Biotechnology · doi:10.1385/mb:32:3:227 · Cited by 279
Krüppel-like Factor 4 Mediates p53-dependent G1/S Cell Cycle Arrest in Response to DNA Damage
Yoon, H. S., Chen, X., & Yang, V. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211027200 · Cited by 265
Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities
He, G., Siddik, Z. H., Huang, Z., Wang, R., Koomen, J., Kobayashi, R., Khokhar, A. R., & Kuang, J. (2005) · Oncogene · doi:10.1038/sj.onc.1208474 · Cited by 264
“As shown in Figure 3d, the level of Thr160-phosphorylated Cdk2 correlated with the level of the total Cdk2 protein during the 36-h DAP treatment, confirming that DAP-induced Cdk inhibition does not involve inhibition of activating phosphorylation of G1-phase Cdks.”
BackgroundInfluentialDutto, I., Tillhon, M., Cazzalini, O., Stivala, L. A., & Prosperi, E. (2015) · Archives of Toxicology · doi:10.1007/s00204-014-1430-4 · Cited by 236
“phorylation (Smits et al. 2000).”
Al Bitar, S., & Gali-Muhtasib, H. (2019) · Cancers · doi:10.3390/cancers11101475 · Cited by 224
“However, mechanisms of p21-mediated G2 phase arrest include inactivating cyclinB/CDK1 complexes [13] by inhibiting CDK-activating kinase (CAK) and thereby inhibiting CDK-1 activating Thr161 phosphorylation [82].”
BackgroundAndo, T., Kawabe, T., Ohara, H., Ducommun, B., Itoh, M., & Okamoto, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106460200 · Cited by 202
p21-Mediated Nuclear Retention of Cyclin B1-Cdk1 in Response to Genotoxic Stress
Charrier-Savournin, F. B., Château, M.-T., Gire, V., Sedivy, J., Piette, J., & Dulić, V. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-12-0871 · Cited by 202
“Although the complexes between cyclin B1 and unphosphorylated Cdk1 have not been described in vivo (Ducommun et al., 1991), they are probably stabilised in the nucleus in the presence of elevated p21 levels (cf. (Smits et al., 2000; Baus et al., 2003).”
BackgroundInfluentialRadiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme
Choi, J., Kim, G., Cho, S. B., & Im, H.-J. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00684-5 · Cited by 195
Stark, G. R., & Taylor, W. R. (2004) · Checkpoint Controls and Cancer · doi:10.1385/1-59259-788-2:051 · Cited by 195
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 194
“While the contribution of p21 to the G2/ M checkpoint arrest is controversial [51], some studies indicate that p21 can inhibit cyclin B1/cdc2 complex activity through physical interaction, thereby displacing Cdc25C from an activating Cdc25C--cyclinB1/cdc2 complex [61], by retaining cyclin B1/cdc2 complexes in the nucl…”
BackgroundTransient Activation of p53 in G2 Phase Is Sufficient to Induce Senescence
Krenning, L., Feringa, F. M., Shaltiel, I. A., van den Berg, J., & Medema, R. H. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.007 · Cited by 193
Self-citationCellular senescence in cancer: from mechanisms to detection
Ou, H., Hoffmann, R., González‐López, C., Doherty, G. J., Korkola, J. E., & Muñoz‐Espín, D. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12807 · Cited by 190
A unified model for the G1/S cell cycle transition
Hume, S., Dianov, G. L., & Ramadan, K. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1002 · Cited by 189
Zhong, W., & Oberley, T. D. (2001) · PubMed · Cited by 183
Deng, T., Yan, G., Song, X., Xie, L., Zhou, Y., Li, J., Hu, X., Li, Z., Hu, J., Zhang, Y., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714938115 · Cited by 162
“The cyclin-dependent kinase (CDK) inhibitor p21 (also known as p21WAF1/Cip1) is a key negative regulator of cell cycle progression, which mediates cell cycle arrest at the G1 or G2 phase in response to a variety of stress stimuli1. p21 contributes to the G1 arrest primarily by inhibiting cyclin E and cyclin A/CDK2 act…”
BackgroundBarnouin, K., Dubuisson, M. L., Child, E. S., Fernandez de Mattos, S., Glassford, J., Medema, R. H., Mann, D. J., & Lam, E. W.-F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111123200 · Cited by 161
Self-citationLi, X., Wang, G., Zhao, J., Ding, H., Cunningham, C., Chen, F., Flynn, D. C., Reed, E., & Li, Q. Q. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5027-1 · Cited by 155
Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts
Baus, F., Gire, V., Fisher, D., Piette, J., & Dulić, V. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg387 · Cited by 143
Cellular effects of CPT‐11 on colon carcinoma cells: Dependence on p53 and hMLH1 status
Magrini, R., Bhonde, M. R., Hanski, M., Notter, M., Scherübl, H., Boland, C. R., Zeitz, M., & Hanski, C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10565 · Cited by 121
Eymin, B., Leduc, C., Coll, J., Brambilla, E. M., & Gazzéri, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206303 · Cited by 137
“At this time, and consistent with passage through mitosis, CDC25C was dephosphorylated at Ser t16 and CDC2 was activated by dephosphorylation at Tyr15 and phosphorylation at Thr161 residues (Figure 4c).”
BackgroundInfluentialMotwani, M., Jung, C. P., Sirotnak, F. M., She, Y., Shah, M. A., Gönen, M., & Schwartz, G. K. (2001) · PubMed · Cited by 116
Less understood issues: p21Cip1 in mitosis and its therapeutic potential
Kreis, N., Louwen, F., & Yuan, J. (2014) · Oncogene · doi:10.1038/onc.2014.133 · Cited by 129
Distinct mechanisms act in concert to mediate cell cycle arrest
Toettcher, J. E., Loewer, A., Ostheimer, G. J., Yaffe, M. B., Tidor, B., & Lahav, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806196106 · Cited by 112
“p21 was previously suggested to inhibit Cdk1-activating kinases (35) or alter the subcellular locations of the Cdk1 complex (36).”
BackgroundG2 arrest in response to topoisomerase II inhibitors: the role of p53.
Clifford, B., Beljin, M., Stark, G. R., & Taylor, W. R. (2003) · PubMed · Cited by 133
Wong, V. K. W., Chiu, P., Chung, S. S. M., Chow, L. M. C., Zhao, Y., Yang, B. B., & Ko, B. C. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0209 · Cited by 112
Rastogi, N., Duggal, S., Singh, S. K., Porwal, K., Srivastava, V. K., Maurya, R., Bhatt, M. L. B., & Mishra, D. P. (2015) · Oncotarget · doi:10.18632/oncotarget.6383 · Cited by 116
“Hence it is plausible from this data that 6G induced proteasome inhibition and oxidative stress through increased ROS stabilized p53 and its downstream targets such as p21 in response to DNA damage [37] resulting in halting of cell cycle progression leading to apoptosis.”
InfluentialBi, G., Liang, J., Zhao, M., Zhang, H., Jin, X. Y., Lu, T., Zheng, Y., Bian, Y., Chen, Z., Huang, Y., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.020 · Cited by 108
“It is widely accepted that CDKN1A induces cell-cycle arrest in different phases and finally leads to growth inhibition by restraining the expression and function of various CDKs,(24,42,47) notably causing G2/M arrest by blocking the activating Thr161 phosphorylation on CDK1, also known as Cdc2, a kinase required for e…”
Yang, D., Tan, M., Wang, G., & Sun, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034079 · Cited by 99
“. In response to DNA damage and mitogen starvation, p21 directly interacts and inhibits cyclin A- and cyclin B-associated CDK1 to block G2/M progression”
BackgroundCell Cycle Regulation and p53 Activation by Protein Phosphatase 2Cα
Ofek, P., Ben‐Meir, D., Kariv-Inbal, Z., Oren, M., & Lavi, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211699200 · Cited by 115
Saussurea lappa induces G2-growth arrest and apoptosis in AGS gastric cancer cells
Ko, S., Kim, H., Jin, D.-H., Bae, H., Kim, S. H., Park, C.-H., & Lee, S. E. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.06.026 · Cited by 92
“After incubation, cells floating and adherent were collected and combined before PI staining and flow cytometric analysis for DNA contents, as explained in the Materials and methods.”
BackgroundInfluentialCdk2 strengthens the intra-S checkpoint and counteracts cell cycle exit induced by DNA damage
Bačević, K., Lossaint, G., Achour, T. N., Georget, V., Fisher, D., & Dulić, V. (2017) · Scientific Reports · doi:10.1038/s41598-017-12868-5 · Cited by 99
Lossaint, G., Besnard, E., Fisher, D., Piette, J., & Dulić, V (2011) · Oncogene · doi:10.1038/onc.2011.135 · Cited by 83
“In NHF exposed to DNA damage after the G1/S transition, p21 not only inhibits cyclin A-Cdk1/2 (Baus et al., 2003) but also sequesters cyclin B1-Cdk1 in the nucleus, thereby preventing its activation by CAK or Cdc25 in the cytoplasm (Charrier-Savournin et al., 2004; Foijer et al., 2005).”
Huang, Z., Wu, Y., Hedrick, N., & Gutmann, D. H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.566-578.2003 · Cited by 87
“Inducible p21CIP1/WAF1 expression causes cell cycle arrest at both G1 and G2 (9, 24, 44) and G2 arrest when p21 CIP1/WAF1 was induced at the beginning of the S phase ( 63 ).”
BackgroundZeng, X., Lin, Y., Yin, C., Zhang, X., Ning, B.-F., Zhang, Q., Zhang, J.-P., Qiu, L., Qin, X.-R., Chen, Y.-X., et al. (2010) · Hepatology · doi:10.1002/hep.24647 · Cited by 82
Yogosawa, S., Yamada, Y., Yasuda, S., Sun, Q., Takizawa, K., & Sakai, T. (2012) · Journal of Natural Products · doi:10.1021/np300465f · Cited by 81
Składanowski, A., Bozko, P. M., & Sabisz, M. (2009) · Chemical Reviews · doi:10.1021/cr900026u · Cited by 77
Kamei, J., Toyofuku, T., & Hori, M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.10.129 · Cited by 78
Visanji, J. M., Thompson, D. G., Padfield, P. J., Duthie, S. J., & Pirie, L. P. (2004) · Journal of Nutrition · doi:10.1093/jn/134.11.3121 · Cited by 69
Liu, L., Yin, Y., Li, Y., Prevedel, L., Lacy, E., Ma, L., & Zhou, P. (2012) · Cell Research · doi:10.1038/cr.2012.48 · Cited by 67
Kleinschmidt, M. A., de Graaf, P., van Teeffelen, H. A. A. M., & Timmers, H. T. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041446 · Cited by 72
“This is in accordance with the finding that overexpression of p21 results in CDK1 inhibition and G2 arrest in U2OS cells [31].”
ResultThe molecular mechanism of G2/M cell cycle arrest induced by AFB1 in the jejunum
Yin, H., Jiang, M., Peng, X., Cui, H., Zhou, Y., He, M., Zuo, Z., Ouyang, P., Fan, J., & Fang, J. S. (2016) · Oncotarget · doi:10.18632/oncotarget.9594 · Cited by 69
“And the relatively low amounts of the formation of an active cyclin B/Cdc2 complex may be the main factor of cells accumulated in G2/M phase [43].”
BackgroundXie, Y., Zhang, H., Sheng, W., Xiang, J., Ye, Z., & Yang, J. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.05.050 · Cited by 69
“inhibit CDC2 activity of cyclin B1/CDC2 complex and induced G2/M arrest [25–28].”
BackgroundIto, K., Nakazato, T., Miyakawa, Y., Yamato, K., Ikeda, Y., & Kizaki, M. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10289 · Cited by 62
“Recent investigations have reported that p21WAF1/CIP1 is involved in the G2/M transition of cell cycle (Li et al., 1994; Caryol et al., 1998; Dulic et al., 1998; Smits et al., 2000).”
BackgroundNam, C., Doi, K., & Nakayama, H. (2010) · PubMed · doi:10.14670/hh-25.485 · Cited by 59
Li, L., Chen, X., Liu, C. C., Lee, L. S., Man, C., & Cheng, S. H. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00128 · Cited by 61
“It has been shown that p21 blocks the activation of the Cdc2-Cyclin B1 complex by preventing the Thr 161 phosphorylation of the Cdc2 subunit (Smits et al., 2000).”
BackgroundChoi, Y. K., Seo, H. S., Choi, H. S., Choi, H. S., Kim, S. R., Shin, Y. C., & Ko, S. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1164-z · Cited by 57
Santos, M. A., van de Werken, C., de Vries, M., Jahr, H., Vromans, M. J. M., Laven, J. S. E., Fauser, B. C. J. M., Kops, G. J. P. L., Lens, S. M. A., & Baart, E. B. (2011) · Human Reproduction · doi:10.1093/humrep/der111 · Cited by 64
Chaudhary, P., Sharma, R., Sahu, M., Vishwanatha, J. K., Awasthi, S., & Awasthi, Y. C. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.467662 · Cited by 55
“We hypothesized a role of p21 in this phenomenon, arguing that the association of p21 with CDK1-cyclin B1 complexes may also down-regulate the CDK1 activity, as shown previously (47, 48).”
BackgroundResidual Cdk1/2 activity after DNA damage promotes senescence
Müllers, E., Silva Cascales, H., Burdova, K., Macurek, L., & Lindqvist, A. (2017) · Aging Cell · doi:10.1111/acel.12588 · Cited by 56
Li, J., Wang, Y., Sun, Y., & Lawrence, T. S. (2002) · Radiation Research · doi:10.1667/0033-7587(2002)157[0322:wttigp]2.0.co;2 · Cited by 53
“Furthermore, there are data to suggest that exogenous overexpression of 14-3-3s or CDKN1A can prevent activation of CDC2 (7, 39).”
BackgroundMasrouha, N., Yang, L., Hijal, S., Larochelle, S., & Suter, B. (2003) · Genetics · doi:10.1093/genetics/163.3.973 · Cited by 62
Mitogen requirement for cell cycle progression in the absence of pocket protein activity
Foijer, F., Wolthuis, R. M. F., Doodeman, V., Medema, R. H., & te Riele, H. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.021 · Cited by 53
“Cells were stained with mouse anti-BrdU (Becton Dickinson) as described in Brugarolas et al. (1998) or stained for MPM2 positivity (Smits et al., 2000a) and subsequently analyzed on FACS using ‘‘Cell Quest’’ software and ‘‘FACS Express’’ software (De Novo Software).”
BackgroundMethodSelf-citationVenkatasubbu, G. D., Ramasamy, S., Avadhani, G. S., Palanikumar, L., & Kumar, J. (2012) · Journal of Nanoparticle Research · doi:10.1007/s11051-012-0819-3 · Cited by 50
“…to inhibit dephosphorylation of Cdc2 at Thr-14 and Tyr-15 and inhibition of cyclin A expression to decrease the formation of cyclin A/Cdc2 complex. p21 has been found to contribute to arrest cell cycle at G2 phase via blocking the activating phosphorylation of Cdc2 on Thr-161 (Smits et al. 2000).”
BackgroundInfluentialWang, W., Li, Q., Bagchi, I. C., & Bagchi, M. K. (2010) · Endocrinology · doi:10.1210/en.2009-1437 · Cited by 49
Wang, Z., Chang, Y., Liu, Y., Liu, B., Zhen, J., Li, X., Lin, J., Yu, Q., Lv, Z., & Wang, R. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.001 · Cited by 47
USP39 promotes the growth of human hepatocellular carcinoma in vitro and in vivo
Yuan, X., Sun, X., Shi, X., Jiang, C., Yu, D., Zhang, W., Guan, W., ZHOU, J., Wu, Y., Qiu, Y., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.4065 · Cited by 47
p21Waf1/Cip1 deficiency causes multiple mitotic defects in tumor cells
Kreis, N., Sanhaji, M., Rieger, M. A., Louwen, F., & Yuan, J. (2013) · Oncogene · doi:10.1038/onc.2013.518 · Cited by 48
Nickel(II)-induced nasal epithelial toxicity and oxidative mitochondrial damage
Lee, Y., Lim, S.-S., Baek, B. J., An, J. M., Nam, H.-S., Woo, K.-M., Cho, M. K., Kim, S.-H., & Lee, S.-H. (2016) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2016.01.005 · Cited by 45
Inhibition of proteasome‐dependent degradation of Wee1 in G 2 ‐arrested Hep3B cells by TGFβ1
Hashimoto, O., Ueno, T., Kimura, R., Ohtsubo, M., Nakamura, T., Koga, H., Torimura, T., Uchida, S., Yamashita, K., & Sata, M. (2003) · Molecular Carcinogenesis · doi:10.1002/mc.10111 · Cited by 45
Lee, Y.-M., Ting, C. M., Cheng, Y., Fan, T., Wong, R. N., Lung, M. L., & Mak, N. K. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.010 · Cited by 47
“Phosphorylation of the conserved threonine-161 residue (Thr161) in cdc2 in nucleus is normally considered as the essential requirement for the cyclin B1/cdc2 complex to drive cells into the mitotic phase [11].”
BackgroundKrishna, B. M., Chaudhary, S., Mishra, D. R., Naik, S. K., Suklabaidya, S., Adhya, A. K., & Mishra, S. K. (2018) · BMC Cancer · doi:10.1186/s12885-018-4528-x · Cited by 52
“p21 is an inhibitor of cyclin dependent kinase belongs to cip and kip family [62], primarily inhibits CDK2 by which it can inhibit cell cycle progression [63, 64].”
BackgroundThe p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression
Fenouille, N., Robert, G., Tichet, M., Puissant, A., Dufies, M., Rocchi, S., Ortonne, J. P., Deckert, M., Ballotti, R., & Tartare‐Deckert, S. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00790.x · Cited by 47
“As p21Cip1 ⁄ Waf1 has been shown to inhibit the activat- ing phosphorylation of cdk1 on threonine 161 (Smits et al., 2000), we analyzed the level of threonine 161 phosphorylation during the time-course of siSPARC.”
BackgroundZivarpour, P., Nikkhah, E., Dana, P. M., Asemi, Z., & Hallajzadeh, J. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00789-x · Cited by 46
“The occurrence of such processes causes further activity of p53 and p21, which responds to DNA damage [10, 106] and, by stopping the cell cycle, causes apoptosis of the cancer cell [10].”
BackgroundMutant MyoD Lacking Cdc2 Phosphorylation Sites Delays M-Phase Entry
Tintignac, L. A. J., Sirri, V., Leibovitch, M.-P., Lécluse, Y., Castedo, M., Métivier, D., Kroemer, G., & Leibovitch, S. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.4.1809-1821.2004 · Cited by 45
“p21 may repress CDK activity by binding directly to cyclin B-Cdc2 complexes (2) (Fig. 5). Moreover, p21 reduces the active phosphorylation of Cdc2 of threonine 161 by Cdk-activating kinase ( 40 ).”
BackgroundLi, Q. Q., Wang, G., Huang, F., Li, J. M., Cuff, C. F., & Reed, E. (2013) · Medical Oncology · doi:10.1007/s12032-013-0488-9 · Cited by 43
Lin, L., Huang, H., & Juan, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044615 · Cited by 40
“CDK1 activation, which is regulated by p21, inhibits G2/M phase arrest, thus promoting mitosis and cell proliferation [30].”
BackgroundThe PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest
Madison, D. L., Stauffer, D. R., & Lundblad, J. R. (2011) · DNA repair · doi:10.1016/j.dnarep.2011.07.006 · Cited by 48
“P21 directly inhibits the CDK1/2 (cdc2) kinases [28], participates in p53-dependent transcriptional repression of cdc25c, cdc2, cyclin B and Chk1 [29] and binds PARP1 [30].”
BackgroundAdorisio, S., Fierabracci, A., Muscari, I., Liberati, A. M., Cannarile, L., Thủy, T. T., Sung, T. V., Sohrab, M. H., Hasan, C. M., Ayroldi, E., et al. (2019) · Toxins · doi:10.3390/toxins11090503 · Cited by 41
“These are two fundamental molecules in proliferation and apoptosis [22,23]. p21 inhibits Cdk-activating kinase (CAK) [24] in G2 phase. p21 also binds with the cyclin B1-Cdk1 complex as a consequence of genotoxicity, thus inhibiting activation by Cdc25 and CAK [25], and can determine G2 block by degradation of cyclin B…”
Additive effect of p53, p21 and Rb deletion in triple knockout primary hepatocytes
Sheahan, S., Bellamy, C. O., Treanor, L. M., Harrison, D. J., & Prost, S. (2003) · Oncogene · doi:10.1038/sj.onc.1207280 · Cited by 42
“It indirectly inhibits cdc2, which is essential for entry into mitosis (Nurse, 1991), through transcriptional activation of p21 (Smits et al., 2000), Gadd45 (Wang et al., 1999) and 14-3-3s (Chan et al., 1999).”
BackgroundYan, L., Donze, J. R., & Liu, L. (2005) · Oncogene · doi:10.1038/sj.onc.1208250 · Cited by 43
“These proteins are also important for G2/M arrest after DNA damage (Kuerbitz et al., 1992; Xiong et al., 1993; Cox and Lane, 1995; Smits et al., 2000; Monte et al., 2003).”
BackgroundWang, J., Chang, L., Lai, X., Li, X., Wang, Z., Huang, Z., Huang, J., & Zhang, G. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1415679 · Cited by 36
“Dephosphorylation of CDK1 and expression of cyclin B1 are required for the activation of the CDK1cyclin B1 complex [23].”
BackgroundAnisomycin suppresses Jurkat T cell growth by the cell cycle-regulating proteins
Yu, C., Xing, F., Tang, Z., Bronner, C., Lu, X., Di, J., Zeng, S., & Liu, J. L. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71019-3 · Cited by 35
Xie, Y. F., Sheng, W., Xiang, J., Zhang, H., Ye, Z., & Yang, J. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0582 · Cited by 40
“32 Therefore, ING4-induced upregulation of p21, 10,14 in a p53-dependent manner, may contribute to the G2 = M arrest seen in Ad-ING4-treated PANC-1 human pancreatic carcinoma cells.”
He, P., Li, Z., Xu, F., Ru, G., Huang, Y., Lin, E., & Peng, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.539485 · Cited by 38
Aberrant histone modification in endometriosis
Nasu, K., Kawano, Y., Kai, K., Aoyagi, Y., Abe, W., Okamoto, M., & Narahara, H. (2014) · Frontiers in bioscience · doi:10.2741/4276 · Cited by 35
Plissonnier, M., Fauconnet, S., Bittard, H., & Lascombe, I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028354 · Cited by 34
“P21 inhibits either Cdc2 kinase activity or prevent its activation by directly binding to Cdc2, thereby blocking the interaction of cyclin B1Cdc2 complexes with their substrates [31].”
BackgroundInduction of p21Cip1-mediated G2/M arrest in H2O2-treated lens epithelial cells.
Seomun, Y., Kim, J.-T., Kim, H.-S., Park, J., & Joo, C. (2005) · PubMed · Cited by 39
Three independent mechanisms for arrest in G2after ionizing radiation
Landsverk, K. S., Patzke, S., Rein, I. D., Stokke, C., Lyng, H., Angelis, P. M. D., & Stokke, T. (2011) · Cell Cycle · doi:10.4161/cc.10.5.14968 · Cited by 37
Y2O3 Nanoparticles and X-ray Radiation-Induced Effects in Melanoma Cells
Porosnicu, I., Butnaru, C. M., Tiseanu, I., Stancu, E., Munteanu, C. V. A., Bita, B. I., Duliu, O. G., & Sima, F. (2021) · Molecules · doi:10.3390/molecules26113403 · Cited by 34
“Furthermore, if the transcription of p21 is high it can also block cell cycle transition from G2 to M phase by binding to the complex formed between CDK1-cyclinB [38].”
BackgroundGe-ping, Q., Xiu, Q., Li, B., Yong-an, L., & Lingzhen, Z. (2009) · Toxicology and Industrial Health · doi:10.1177/0748233709345936 · Cited by 33
“The CDC2 (CDK1) is activated specially at the G2/M transition, and the activation of CDC2 requires binding to Cyclin B1 and phosphorylation of CDC2 on the threonine at position 161 (Thr 161; Smits et al., 2000).”
BackgroundChoi, H. J., Yee, S.-B., Park, S.-E., Im, E., Jung, J. H., Chung, H. Y., Choi, Y. H., & Kim, N. D. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.02.030 · Cited by 33
“Recent investigations have reported that p21 is involved in the G2/M transition of cell cycle [44–48].”
BackgroundLee, E. J., Gerhold, M., Palmer, M. W., & Christen, R. D. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600779 · Cited by 35
“Indeed, p21 protein has been shown to inhibit phosphorylation of Cdc2 and to enforce G2 arrest (Smits et al, 2000).”
BackgroundDNA Damage Stress: Cui Prodest?
Verma, N., Franchitto, M., Zonfrilli, A., Cialfi, S., Palermo, R., & Talora, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051073 · Cited by 33
Cyclic Pifithrin-α Sensitizes Wild Type p53 Tumor Cells to Antimicrotubule Agent–Induced Apoptosis
Zuco, V., & Zunino, F. (2008) · Neoplasia · doi:10.1593/neo.08262 · Cited by 31
Kolb, R. H., Greer, P. M., Cao, P. T., Cowan, K. H., & Yan, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050281 · Cited by 31
“Moreover, although p53 induced p21 is a poor inhibitor of Cdc2 in vitro compared to other cyclindependent kinases [36], some evidence suggest p21 may prevent interaction between Cdc2 and its activator Cdc25C phosphatase [37] as well as the Cdc2 activation by CAK kinase [38].”
BackgroundSonic hedgehog signaling pathway mediates development of hepatocellular carcinoma
Cai, H., Li, H., Li, J., Li, X., Li, Y., Shi, Y., & Wang, D. (2016) · Tumor Biology · doi:10.1007/s13277-016-5463-6 · Cited by 31
“Subsequently, the released cyclin B1 translocates to the nucleus and activates MPF to promote G2/M transition [2, 21, 22].”
BackgroundThe role of cell cycle proteins in Glomerular disease
Griffin, S., Pichler, R. H., Wada, T., Vaughan, M., Durvasula, R. V., & Shankland, S. J. (2003) · Seminars in Nephrology · doi:10.1053/s0270-9295(03)00133-5 · Cited by 31
Zinc-induced G2/M blockage is p53 and p21 dependent in normal human bronchial epithelial cells
Wong, S. H. K., Shih, R. S. M., Schoene, N. W., & Lei, K. Y. (2008) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00061.2008 · Cited by 30
Metadata
- Authors
- Smits, V. A. J., Klompmaker, R., Vallenius, T., Rijksen, G., Mäkelä, T. P., & Medema, R. H.
- Affiliations
- University Medical Center Utrecht (NL)
- University of Helsinki (FI)
- Corresponding author
- Medema, René H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-09
- Volume
- 275
- Issue
- 39
- Pages
- 30638-30643
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2127397312
- Cited by
- 221
- References
- 41
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 11 · 2020: 7 · 2019: 6 · 2018: 4 · 2017: 12 · 2016: 14 · 2015: 7 · 2014: 6 · 2013: 14 · 2012: 14
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7349 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- p21, cdc2, G2 checkpoint, DNA damage checkpoint, G2 cell cycle arrest, cyclin-dependent kinase inhibition, Chk1, Cdc25C, cell cycle regulation
- MeSH terms
- Cell Compartmentation, Cell Nucleus, DNA Damage, Models, Biological, Phosphorylation, Protein Binding, Threonine, G2 Phase, CDC2 Protein Kinase, Cyclins, Cyclin-Dependent Kinases, Cyclin B, Cyclin-Dependent Kinase Inhibitor p21
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.